These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2402267)

  • 1. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Gold R; Meurers B; Reichmann H
    N Engl J Med; 1990 Oct; 323(14):994. PubMed ID: 2402267
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
    N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
    Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
    Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine.
    Herzberg NH; Zorn I; Zwart R; Portegies P; Bolhuis PA
    Muscle Nerve; 1992 Jun; 15(6):706-10. PubMed ID: 1324428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV or zidovudine myopathy?
    Dalakas M
    Neurology; 1994 Feb; 44(2):360-1; author reply 362-4. PubMed ID: 8309594
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy.
    Scruggs ER; Dirks Naylor AJ
    Pharmacology; 2008; 82(2):83-8. PubMed ID: 18504416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV or zidovudine myopathy?
    Gherardi R; Chariot P
    Neurology; 1994 Feb; 44(2):361-2; author reply 362-4. PubMed ID: 8309597
    [No Abstract]   [Full Text] [Related]  

  • 8. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
    Pezeshkpour G; Illa I; Dalakas MC
    Hum Pathol; 1991 Dec; 22(12):1281-8. PubMed ID: 1748434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
    Schröder JM; Bertram M; Schnabel R; Pfaff U
    Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Muscular involvement in HIV infection].
    Gherardi R; Chariot P; Authier FJ
    Rev Neurol (Paris); 1995 Nov; 151(11):603-7. PubMed ID: 8745623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
    Lane RJ; McLean KA; Moss J; Woodrow DF
    Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Muscular complications in HIV infection].
    Authier FJ; Chariot P; Gherardi R
    Arch Anat Cytol Pathol; 1997; 45(2-3):174-8. PubMed ID: 9382610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection.
    Chen SC; Barker SM; Mitchell DH; Stevens SM; O'Neill P; Cunningham AL
    Pathology; 1992 Apr; 24(2):109-11. PubMed ID: 1641255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of HIV-associated myopathy by zidovudine.
    Berger JR; Shebert R; Gregorios JB
    AIDS; 1991 Feb; 5(2):229-30. PubMed ID: 2031699
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
    Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
    Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients.
    Weissman JD; Constantinitis I; Hudgins P; Wallace DC
    Neurology; 1992 Mar; 42(3 Pt 1):619-23. PubMed ID: 1549225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Images in clinical medicine. Zidovudine myopathy.
    Chariot P
    N Engl J Med; 1993 Jun; 328(23):1675. PubMed ID: 11407398
    [No Abstract]   [Full Text] [Related]  

  • 18. [Toxic drug-induced proximal myopathy in CDC C3 HIV-infection].
    Weisser M
    Praxis (Bern 1994); 1997 Oct; 86(43):1708-10. PubMed ID: 9432697
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.
    Semino-Mora MC; Leon-Monzon ME; Dalakas MC
    Lab Invest; 1994 Jul; 71(1):102-12. PubMed ID: 7518879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
    Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
    Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.